CURIS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CURIS, INC. (CRIS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $569.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- CURIS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $569.00K, a 49.87% decline year-over-year.
- CURIS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $575.00K, a 50.60% decline year-over-year.
- CURIS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $924.00K, a 33.24% decline year-over-year.
- CURIS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.14M, a 33.39% decline year-over-year.
- CURIS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.02M, a 32.21% decline from fiscal 2024.
- CURIS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.93M, a 1.22% decline from fiscal 2023.
- CURIS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $6.00M, a 11.14% decline from fiscal 2022.
- CURIS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.75M, a 27.90% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $569.00K 10-Q · filed 2026-08-14 | $1.14M derived: sum of 2 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $575.00K 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | $4.02M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | $924.00K 10-Q · filed 2025-11-06 | $2.06M derived: sum of 2 quarters · filed 2026-08-14 | $3.22M derived: sum of 3 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $1.14M 10-Q · filed 2026-08-14 | $2.30M derived: sum of 2 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $1.16M 10-Q · filed 2026-08-14 | ||||
| 2024-12-31 | $5.93M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | $1.38M 10-Q · filed 2025-11-06 | $3.09M derived: sum of 2 quarters · filed 2025-11-06 | $4.65M derived: sum of 3 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $1.70M 10-Q · filed 2025-11-06 | $3.26M derived: sum of 2 quarters · filed 2025-11-06 | |||
| 2024-03-31 | $1.56M 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $6.00M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $1.63M 10-Q · filed 2024-11-14 | $3.06M derived: sum of 2 quarters · filed 2024-11-14 | $4.45M derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $1.42M 10-Q · filed 2024-11-14 | $2.82M derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $1.40M 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $6.75M 10-K · filed 2024-02-08 | ||||
| 2022-09-30 | $1.32M 10-Q · filed 2023-11-02 | $3.29M derived: sum of 2 quarters · filed 2023-11-02 | $5.01M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $1.97M 10-Q · filed 2023-11-02 | $3.68M derived: sum of 2 quarters · filed 2023-11-02 | |||
| 2022-03-31 | $1.72M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $5.28M 10-K · filed 2023-03-13 | ||||
| 2021-09-30 | $1.46M 10-Q · filed 2022-11-09 | $2.74M derived: sum of 2 quarters · filed 2022-11-09 | $3.84M derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $1.27M 10-Q · filed 2022-11-09 | $2.37M derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $1.10M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $2.70M 10-K · filed 2022-02-24 | ||||
| 2020-09-30 | $624.00K 10-Q · filed 2021-11-09 | $1.21M derived: sum of 2 quarters · filed 2021-11-09 | $1.83M derived: sum of 3 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $585.00K 10-Q · filed 2021-11-09 | $1.21M derived: sum of 2 quarters · filed 2021-11-09 | |||
| 2020-03-31 | $625.00K 10-Q · filed 2021-11-09 | ||||
| 2019-12-31 | $2.66M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $684.00K 10-Q · filed 2020-11-10 | $1.31M derived: sum of 2 quarters · filed 2020-11-10 | $1.97M derived: sum of 3 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $631.00K 10-Q · filed 2020-11-10 | $1.28M derived: sum of 2 quarters · filed 2020-11-10 | |||
| 2019-03-31 | $651.00K 10-Q · filed 2020-11-10 | ||||
| 2018-12-31 | $3.94M 10-K · filed 2020-03-19 | ||||
| 2018-06-30 | $1.19M 10-Q · filed 2019-11-05 | $2.42M derived: sum of 2 quarters · filed 2019-11-05 | |||
| 2018-03-31 | $1.23M 10-Q · filed 2019-11-05 | ||||
| 2017-12-31 | $5.37M 10-K · filed 2019-03-26 | ||||
| 2016-12-31 | $4.29M 10-K · filed 2018-03-08 | ||||
| 2015-12-31 | $3.58M 10-K · filed 2018-03-08 | $3.58M 10-K · filed 2016-02-29 | |||
| 2014-12-31 | $3.14M 10-K · filed 2017-03-09 | $3.14M 10-K · filed 2015-02-24 | |||
| 2013-12-31 | $2.65M 10-K · filed 2016-02-29 | ||||
| 2012-12-31 | $3.27M 10-K · filed 2015-02-24 | ||||
| 2011-12-31 | $1.64M 10-K · filed 2014-03-13 | ||||
| 2010-12-31 | $1.98M 10-K · filed 2013-03-13 | ||||
| 2009-12-31 | $1.75M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |